Xanthone
(Synonyms: 呫吨酮) 目录号 : GC17356
A xanthone scaffold
Cas No.:90-47-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Xanthone shows the antagonism of endogenous nitric oxide synthase (NOS) inhibitors, it has antitumor, antihepatotoxic, anti-inflammatory and antimicrobial activities [1]. Two derivatives of xanthone potently inhibited nitric oxide synthesis with IC50 values of 4.3 and 4.4 μM, respectively [2].
In endothelial cells, NOS synthesizes nitric oxide (NO) from L-arginine. In the maintenance of vascular structure and tone, NO has been thought to play a key role [1].
Asymmetric dimethylarginine (ADMA) is synthesized by protein arginine methyltransferases (PRMTs), using S-adenosylmethionine as methyl group donor. Dimethylarginine dimethylaminohydrolase (DDAH) degrades ADMA to L-citrulline and dimethylamine. There are two different isoforms of DDAH, DDAH-1 and DDAH-2. Typically, DDAH-1 is found in tissues containing neuronal NOS, whereas DDAH-2 predominates in tissues expressing the endothelial isoform of NOS. In cultured endothelial cells, xanthones showed the inhibition of the upregulation of MCP-1 expression, the enhancement of monocytes adhesion and the increase in the release of LDH, concomitantly with the reduction of ADMA levels. These results suggest that xanthones protect against high-lipid-level-induced endothelial damage. This protective effect of xanthones is related to the reduction of ADMA concentration [1].
A single injection of native LDL caused a rapid accumulation and oxidation of LDL in the arterial wall. At 6 to 12 h after injection of LDL, ICAM-1 expression increased and led to endothelial dysfunction and an elevation of ADMA level. In vivo, pretreatment with xanthones attenuated the effect of the injection of LDL [1].
References:
[1]. Jiang DJ, Dai Z and Li YJ. Pharmacological effects of xanthones as cardiovascular protective agents. Cardiovasc Drug Rev, 2004, 22(2):91-102.
[2]. Boonnak N, Khamthip A, Karalai C, et al. Nitric Oxide Inhibitory Activity of Xanthones from the Green Fruits of Cratoxylum formosum ssp. pruniflorum. Australian Journal of Chemistry, 2010, 63(11):1550-1556.
| Cas No. | 90-47-1 | SDF | |
| 别名 | 呫吨酮 | ||
| 化学名 | 9H-xanthen-9-one | ||
| Canonical SMILES | O=C1C2=CC=CC=C2OC3=CC=CC=C31 | ||
| 分子式 | C13H8O2 | 分子量 | 196.2 |
| 溶解度 | DMSO : 10 mg/mL (50.97 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0968 mL | 25.4842 mL | 50.9684 mL |
| 5 mM | 1.0194 mL | 5.0968 mL | 10.1937 mL |
| 10 mM | 0.5097 mL | 2.5484 mL | 5.0968 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。